Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Syndicate
Global Blood Therapeutics files $200M mixed securities shelf  17:28
08/05/20
08/05
17:28
08/05/20
17:28
GBT

Global Blood Therapeutics

$67.87 /

-0.88 (-1.28%)

 
ShowHide Related Items >><<
GBT Global Blood Therapeutics
$67.87 /

-0.88 (-1.28%)

GBT Global Blood Therapeutics
$67.87 /

-0.88 (-1.28%)

07/20/20 Roth Capital
Global Blood Therapeutics initiated with a Buy at Roth Capital
07/13/20 BofA
Global Blood Therapeutics initiated with a Buy at BofA
07/01/20 Goldman Sachs
Global Blood Therapeutics upgraded to Buy from Neutral at Goldman Sachs
06/12/20 Wells Fargo
Global Blood's Oxbryta efficacy bar 'tough to surpass,' says Wells Fargo
GBT Global Blood Therapeutics
$67.87 /

-0.88 (-1.28%)

GBT Global Blood Therapeutics
$67.87 /

-0.88 (-1.28%)

Earnings
Global Blood Therapeutics reports Q2 EPS (86c), consensus ($1.15) » 16:05
08/05/20
08/05
16:05
08/05/20
16:05
GBT

Global Blood Therapeutics

$68.15 /

-0.605 (-0.88%)

Reports Q2 revenue…

Reports Q2 revenue $31.5M, consensus $19.03M. The company said, "In the second quarter of 2020, we continued to make important progress on GBT's vision of being a leading biopharmaceutical company and the leader in sickle cell disease. Despite the impact of COVID-19, we continued to successfully execute the launch of Oxbryta and make significant progress on new prescriptions, new prescribers, and payer coverage. During the quarter, we were pleased to see increased use of virtual engagements and telemedicine by healthcare professionals and continued growth of Oxbryta prescriptions. In addition, we made significant progress in our efforts to expand the approved use of Oxbryta for more patients in the United States and in Europe, with regulatory submissions planned by mid-2021."

ShowHide Related Items >><<
GBT Global Blood Therapeutics
$68.15 /

-0.605 (-0.88%)

GBT Global Blood Therapeutics
$68.15 /

-0.605 (-0.88%)

07/20/20 Roth Capital
Global Blood Therapeutics initiated with a Buy at Roth Capital
07/13/20 BofA
Global Blood Therapeutics initiated with a Buy at BofA
07/01/20 Goldman Sachs
Global Blood Therapeutics upgraded to Buy from Neutral at Goldman Sachs
06/12/20 Wells Fargo
Global Blood's Oxbryta efficacy bar 'tough to surpass,' says Wells Fargo
GBT Global Blood Therapeutics
$68.15 /

-0.605 (-0.88%)

GBT Global Blood Therapeutics
$68.15 /

-0.605 (-0.88%)

Conference/Events
FedEx participates in a conference call with Credit Suisse » 09:25
08/05/20
08/05
09:25
08/05/20
09:25
FDX

FedEx

$170.67 /

+1.42 (+0.84%)

Conference call to be…

Conference call to be held on August 5 at 10 am hosted by Credit Suisse.

ShowHide Related Items >><<
FDX FedEx
$170.67 /

+1.42 (+0.84%)

FDX FedEx
$170.67 /

+1.42 (+0.84%)

07/06/20 Argus
FedEx upgraded to Buy from Hold earlier at Argus
07/02/20 Deutsche Bank
FedEx price target raised to $150 from $128 at Deutsche Bank
07/01/20
Fly Intel: Top five analyst upgrades
07/01/20 Cowen
FedEx price target raised to $167 from $156 at Cowen
FDX FedEx
$170.67 /

+1.42 (+0.84%)

FDX FedEx
$170.67 /

+1.42 (+0.84%)

FDX FedEx
$170.67 /

+1.42 (+0.84%)

FDX FedEx
$170.67 /

+1.42 (+0.84%)

Conference/Events
FedEx participates in a conference call with Credit Suisse » 07:28
08/05/20
08/05
07:28
08/05/20
07:28
FDX

FedEx

$170.67 /

+1.42 (+0.84%)

Conference call to be…

Conference call to be held on August 5 at 10 am hosted by Credit Suisse.

ShowHide Related Items >><<
FDX FedEx
$170.67 /

+1.42 (+0.84%)

FDX FedEx
$170.67 /

+1.42 (+0.84%)

07/06/20 Argus
FedEx upgraded to Buy from Hold earlier at Argus
07/02/20 Deutsche Bank
FedEx price target raised to $150 from $128 at Deutsche Bank
07/01/20
Fly Intel: Top five analyst upgrades
07/01/20 Cowen
FedEx price target raised to $167 from $156 at Cowen
FDX FedEx
$170.67 /

+1.42 (+0.84%)

FDX FedEx
$170.67 /

+1.42 (+0.84%)

FDX FedEx
$170.67 /

+1.42 (+0.84%)

FDX FedEx
$170.67 /

+1.42 (+0.84%)

Conference/Events
FedEx participates in a conference call with Stephens » 04:55
08/05/20
08/05
04:55
08/05/20
04:55
FDX

FedEx

$170.67 /

+1.42 (+0.84%)

Conference call to be…

Conference call to be held on August 5 at 10 am hosted by Stephens.

ShowHide Related Items >><<
FDX FedEx
$170.67 /

+1.42 (+0.84%)

FDX FedEx
$170.67 /

+1.42 (+0.84%)

07/06/20 Argus
FedEx upgraded to Buy from Hold earlier at Argus
07/02/20 Deutsche Bank
FedEx price target raised to $150 from $128 at Deutsche Bank
07/01/20
Fly Intel: Top five analyst upgrades
07/01/20 Cowen
FedEx price target raised to $167 from $156 at Cowen
FDX FedEx
$170.67 /

+1.42 (+0.84%)

FDX FedEx
$170.67 /

+1.42 (+0.84%)

FDX FedEx
$170.67 /

+1.42 (+0.84%)

FDX FedEx
$170.67 /

+1.42 (+0.84%)

Tuesday
Conference/Events
FedEx participates in a conference call with Stephens » 15:38
08/04/20
08/04
15:38
08/04/20
15:38
FDX

FedEx

$171.03 /

+1.78 (+1.05%)

Conference call to be…

Conference call to be held on August 5 at 10 am hosted by Stephens.

ShowHide Related Items >><<
FDX FedEx
$171.03 /

+1.78 (+1.05%)

FDX FedEx
$171.03 /

+1.78 (+1.05%)

07/06/20 Argus
FedEx upgraded to Buy from Hold earlier at Argus
07/02/20 Deutsche Bank
FedEx price target raised to $150 from $128 at Deutsche Bank
07/01/20
Fly Intel: Top five analyst upgrades
07/01/20 Cowen
FedEx price target raised to $167 from $156 at Cowen
FDX FedEx
$171.03 /

+1.78 (+1.05%)

FDX FedEx
$171.03 /

+1.78 (+1.05%)

FDX FedEx
$171.03 /

+1.78 (+1.05%)

FDX FedEx
$171.03 /

+1.78 (+1.05%)

Conference/Events
William Blair to hold a virtual conference » 09:55
08/04/20
08/04
09:55
08/04/20
09:55
RCUS

Arcus Biosciences

$20.42 /

-0.61 (-2.90%)

, AGEN

Agenus

$3.20 /

-0.055 (-1.69%)

, EXEL

Exelixis

$23.06 /

-0.64 (-2.70%)

, CALA

Calithera Biosciences

$4.85 /

-0.02 (-0.41%)

, RGEN

Repligen

$155.50 /

-3.02 (-1.91%)

, PIRS

Pieris Pharmaceuticals

$2.68 /

-0.025 (-0.92%)

, CYAD

Celyad

$9.87 /

+ (+0.00%)

, FATE

Fate Therapeutics

$32.33 /

-0.92 (-2.77%)

, CLLS

Cellectis

$17.44 /

+ (+0.00%)

, AUTL

Autolus Therapeutics

$13.92 /

+ (+0.00%)

, GRTS

Gritstone Oncology

$3.35 /

+0.03 (+0.90%)

, ADPT

Adaptive Biotechnologies

$39.49 /

+0.12 (+0.30%)

, TBIO

Translate Bio

$15.60 /

-0.14 (-0.89%)

, EBS

Emergent BioSolutions

$122.01 /

+4.045 (+3.43%)

, ITCI

Intra-Cellular

$20.77 /

-0.15 (-0.72%)

, KRTX

Karuna Therapeutics

$86.82 /

-0.68 (-0.78%)

, ASMB

Assembly Biosciences

$23.15 /

+0.03 (+0.13%)

, NCNA

NuCana

$6.55 /

+0.4 (+6.50%)

, AXSM

Axsome Therapeutics

$74.50 /

-1.82 (-2.38%)

, OVID

Ovid Therapeutics

$6.61 /

-0.16 (-2.36%)

, ALLK

Allakos

$78.92 /

-0.57 (-0.72%)

, NBIX

Neurocrine

$124.09 /

+0.92 (+0.75%)

, XENE

Xenon Pharmaceuticals

$11.51 /

+ (+0.00%)

, CRSP

Crispr Therapeutics

$91.70 /

-0.85 (-0.92%)

, BEAM

Beam Therapeutics

$19.00 /

+0.03 (+0.16%)

, GBT

Global Blood Therapeutics

$68.59 /

-2.08 (-2.94%)

, IONS

Ionis Pharmaceuticals

$58.45 /

-0.78 (-1.32%)

, RTRX

Retrophin

$20.19 /

+ (+0.00%)

Biotech Focus Virtual…

Biotech Focus Virtual Conference 2020 will be held on August 4-6 beginning at 10 am on August 4. Webcast Link

ShowHide Related Items >><<
XENE Xenon Pharmaceuticals
$11.51 /

+ (+0.00%)

TBIO Translate Bio
$15.60 /

-0.14 (-0.89%)

RTRX Retrophin
$20.19 /

+ (+0.00%)

RGEN Repligen
$155.50 /

-3.02 (-1.91%)

RCUS Arcus Biosciences
$20.42 /

-0.61 (-2.90%)

PIRS Pieris Pharmaceuticals
$2.68 /

-0.025 (-0.92%)

OVID Ovid Therapeutics
$6.61 /

-0.16 (-2.36%)

NCNA NuCana
$6.55 /

+0.4 (+6.50%)

NBIX Neurocrine
$124.09 /

+0.92 (+0.75%)

KRTX Karuna Therapeutics
$86.82 /

-0.68 (-0.78%)

ITCI Intra-Cellular
$20.77 /

-0.15 (-0.72%)

IONS Ionis Pharmaceuticals
$58.45 /

-0.78 (-1.32%)

GRTS Gritstone Oncology
$3.35 /

+0.03 (+0.90%)

GBT Global Blood Therapeutics
$68.59 /

-2.08 (-2.94%)

FATE Fate Therapeutics
$32.33 /

-0.92 (-2.77%)

EXEL Exelixis
$23.06 /

-0.64 (-2.70%)

EBS Emergent BioSolutions
$122.01 /

+4.045 (+3.43%)

CYAD Celyad
$9.87 /

+ (+0.00%)

CRSP Crispr Therapeutics
$91.70 /

-0.85 (-0.92%)

CLLS Cellectis
$17.44 /

+ (+0.00%)

CALA Calithera Biosciences
$4.85 /

-0.02 (-0.41%)

BEAM Beam Therapeutics
$19.00 /

+0.03 (+0.16%)

AXSM Axsome Therapeutics
$74.50 /

-1.82 (-2.38%)

AUTL Autolus Therapeutics
$13.92 /

+ (+0.00%)

ASMB Assembly Biosciences
$23.15 /

+0.03 (+0.13%)

ALLK Allakos
$78.92 /

-0.57 (-0.72%)

AGEN Agenus
$3.20 /

-0.055 (-1.69%)

ADPT Adaptive Biotechnologies
$39.49 /

+0.12 (+0.30%)

RCUS Arcus Biosciences
$20.42 /

-0.61 (-2.90%)

06/10/20 Truist
Arcus Biosciences price target raised to $45 from $22 at SunTrust
06/03/20 SVB Leerink
Gilead upgraded to Outperform at SVB Leerink on remdesivir sales, Arcus deal
06/02/20 Citi
Arcus Biosciences price target raised to $41 from $15 at Citi
05/27/20 Raymond James
Raymond James keeps Market Perform on Gilead following Arcus partnership
AGEN Agenus
$3.20 /

-0.055 (-1.69%)

01/09/20 B. Riley FBR
Arbutus Biopharma price target raised to $6 from $3 at B. Riley FBR
11/19/19
Fly Intel: Top five analyst initiations
11/19/19 B. Riley FBR
Agenus resumed with a Buy at B. Riley FBR
11/19/19 B. Riley FBR
Agenus resumed with a Buy at B. Riley FBR
EXEL Exelixis
$23.06 /

-0.64 (-2.70%)

06/30/20 Piper Sandler
Exelixis' 2/3 Phase III Contact studies underway, says Piper Sandler
05/14/20 Truist
Exelixis price target raised to $40 from $35 at SunTrust
05/13/20 Piper Sandler
Exelixis mCRPC data for CABOMETYX may accelerate approval, says Piper Sandler
05/06/20 Piper Sandler
Exelixis price target raised to $30 from $23 at Piper Sandler
CALA Calithera Biosciences
$4.85 /

-0.02 (-0.41%)

05/11/20 Citi
Calithera Biosciences price target raised to $10 from $7 at Citi
05/08/20 H.C. Wainwright
Calithera Biosciences price target raised to $9.50 from $7 at H.C. Wainwright
03/27/20
Fly Intel: Top five analyst initiations
03/27/20 Jefferies
Jefferies starts Calithera at Buy ahead of three data catalysts
RGEN Repligen
$155.50 /

-3.02 (-1.91%)

06/30/20 H.C. Wainwright
Repligen price target raised to $151 from $143 at H.C. Wainwright
05/27/20 Stifel
Repligen price target raised to $150 from $135 at Stifel
05/07/20 Craig-Hallum
Repligen price target raised to $145 from $120 at Craig-Hallum
05/07/20 H.C. Wainwright
Repligen price target raised to $143 from $100 at H.C. Wainwright
PIRS Pieris Pharmaceuticals
$2.68 /

-0.025 (-0.92%)

03/13/20 Baird
Baird upgrades Pieris Pharmaceuticals as pipeline updates expected
03/13/20 Baird
Pieris Pharmaceuticals upgraded to Outperform from Neutral at Baird
03/12/20 H.C. Wainwright
Increased visibility in 2020 expected for Pieris, says H.C. Wainwright
01/27/20 H.C. Wainwright
Pieris Pharmaceuticals price target raised to $9 from $7 at H.C. Wainwright
CYAD Celyad
$9.87 /

+ (+0.00%)

03/26/20 Wells Fargo
Celyad price target lowered to $20 from $44 at Wells Fargo
03/25/20 H.C. Wainwright
Celyad price target lowered to $37 from $43 at H.C. Wainwright
FATE Fate Therapeutics
$32.33 /

-0.92 (-2.77%)

06/10/20 Oppenheimer
Fate Therapeutics price target raised to $40 from $34 at Oppenheimer
06/09/20 Piper Sandler
Fate Therapeutics price target lowered to $59 from $63 at Piper Sandler
05/13/20
Fly Intel: Top five analyst initiations
05/13/20 H.C. Wainwright
Fate Therapeutics initiated with a Buy at H.C. Wainwright
CLLS Cellectis
$17.44 /

+ (+0.00%)

05/12/20
Fly Intel: Top five analyst initiations
05/11/20 Baird
Cellectis initiated with an Outperform at Baird
03/06/20 Citi
Cellectis price target raised to $16 from $14 at Citi
03/06/20 Goldman Sachs
Cellectis downgraded to Sell from Neutral at Goldman Sachs
AUTL Autolus Therapeutics
$13.92 /

+ (+0.00%)

07/31/20
Fly Intel: Top five analyst initiations
07/31/20 JPMorgan
Autolus Therapeutics initiated with an Overweight at JPMorgan
07/22/20 Truist
Autolus Therapeutics initiated with a Buy at SunTrust
07/22/20 Truist
Autolus Therapeutics initiated with a Buy at SunTrust
GRTS Gritstone Oncology
$3.35 /

+0.03 (+0.90%)

07/14/20 BTIG
Gritstone Oncology price target lowered to $17 from $31 at BTIG
ADPT Adaptive Biotechnologies
$39.49 /

+0.12 (+0.30%)

06/18/20 Guggenheim
Adaptive to benefit from increased MRD testing by oncologists, says Guggenheim
06/03/20
Fly Intel: Top five analyst initiations
06/03/20 Goldman Sachs
Adaptive Biotechnologies initiated with a Buy at Goldman Sachs
05/19/20 Guggenheim
Adaptive Biotechnologies price target raised to $50 from $44 at Guggenheim
TBIO Translate Bio
$15.60 /

-0.14 (-0.89%)

07/07/20 H.C. Wainwright
Translate Bio price target raised to $32 from $18 at H.C. Wainwright
07/06/20
Fly Intel: Top five analyst initiations
07/06/20 William Blair
Translate Bio initiated with an Outperform at William Blair
06/26/20 Truist
Translate Bio initiated with a Buy at SunTrust
EBS Emergent BioSolutions
$122.01 /

+4.045 (+3.43%)

07/17/20 Cantor Fitzgerald
Emergent BioSolutions price target raised to $110 from $85 at Cantor Fitzgerald
07/02/20 Wells Fargo
Emergent BioSolutions price target raised to $93 from $85 at Wells Fargo
06/26/20 Raymond James
Vaxart already had vaccine deals with Emergent, Kindred, notes Raymond James
06/08/20 Guggenheim
Emergent BioSolutions price target lowered to $87 from $101 at Guggenheim
ITCI Intra-Cellular
$20.77 /

-0.15 (-0.72%)

06/04/20 Cantor Fitzgerald
Cantor reiterates $37 target on Intra-Cellular ahead of Phase 3 data
03/03/20 BTIG
Intra-Cellular price target lowered to $68 from $73 at BTIG
02/20/20
Fly Intel: Top five analyst initiations
02/19/20 Evercore ISI
Intra-Cellular initiated with an Outperform at Evercore ISI
KRTX Karuna Therapeutics
$86.82 /

-0.68 (-0.78%)

06/24/20 Oppenheimer
Karuna Therapeutics price target raised to $135 from $125 at Oppenheimer
06/02/20 Wedbush
Karuna Therapeutics price target raised to $126 from $117 at Wedbush
06/01/20 Goldman Sachs
Karuna price target raised to $131 from $115 at Goldman Sachs
05/31/20 Stifel
Karuna schizophrenia drug has blockbuster potential, says Stifel
ASMB Assembly Biosciences
$23.15 /

+0.03 (+0.13%)

07/21/20 Baird
Assembly Biosciences HBV deal a positive, says Baird
07/20/20 Piper Sandler
BeiGene inked smart deal with Assembly, says Piper Sandler
06/02/20 Mizuho
New clinical paper potentially supports Assembly stoppage criteria, says Mizuho
10/17/19 Baird
Assembly Biosciences abstract data encouraging, says Baird
NCNA NuCana
$6.55 /

+0.4 (+6.50%)

07/24/20
Fly Intel: Top five analyst initiations
07/24/20 Oppenheimer
NuCana initiated with an Outperform at Oppenheimer
07/23/20 Oppenheimer
NuCana initiated with an Outperform at Oppenheimer
01/27/20 William Blair
NuCana undervalued as first patients dosed in Phase 3 study, says William Blair
AXSM Axsome Therapeutics
$74.50 /

-1.82 (-2.38%)

07/13/20 Oppenheimer
Relmada Therapeutics initiated with an Outperform at Oppenheimer
04/28/20 Guggenheim
Axsome Therapeutics price target raised to $200 from $158 at Guggenheim
04/28/20 Truist
Axsome Therapeutics price target raised to $200 from $145 at SunTrust
04/28/20 Cantor Fitzgerald
Axsome Therapeutics price target raised to $131 from $125 at Cantor Fitzgerald
OVID Ovid Therapeutics
$6.61 /

-0.16 (-2.36%)

07/14/20 Citi
Ovid Therapeutics price target raised to $9 from $8 at Citi
06/18/20 Cantor Fitzgerald
Ovid Therapeutics price target raised to $13 from $7 at Cantor Fitzgerald
05/22/20 Cantor Fitzgerald
Zynerba price target raised to $21 from $12 at Cantor Fitzgerald
05/07/20 Piper Sandler
Ovid's gaboxadol data in Fragile X 'promising,' says Piper Sandler
ALLK Allakos
$78.92 /

-0.57 (-0.72%)

03/25/20 Jefferies
Allakos starts two pivotals on time despite skepticism, says Jefferies
03/12/20 SMBC Nikko
Allakos initiated with an Underperform at SMBC Nikko
02/27/20 Barclays
Allakos initiated with an Underweight at Barclays
02/27/20 Barclays
Allakos initiated with an Underweight at Barclays
NBIX Neurocrine
$124.09 /

+0.92 (+0.75%)

08/04/20 Canaccord
Neurocrine price target raised to $145 from $134 at Canaccord
08/04/20 SVB Leerink
Neurocrine price target raised to $120 from $105 at SVB Leerink
08/04/20 Piper Sandler
Neurocrine price target raised to $145 from $141 at Piper Sandler
08/04/20 H.C. Wainwright
Neurocrine price target raised to $140 from $131 at H.C. Wainwright
XENE Xenon Pharmaceuticals
$11.51 /

+ (+0.00%)

07/21/20
Fly Intel: Top five analyst initiations
07/21/20 Needham
Xenon Pharmaceuticals initiated with a Buy at Needham
07/20/20 Needham
Xenon Pharmaceuticals initiated with a Buy at Needham
06/01/20
Fly Intel: Top five analyst initiations
CRSP Crispr Therapeutics
$91.70 /

-0.85 (-0.92%)

07/28/20 Needham
Crispr Therapeutics price target raised to $105 from $84 at Needham
07/28/20 Wells Fargo
Crispr Therapeutics price target raised to $110 from $95 at Wells Fargo
07/28/20 Oppenheimer
Crispr Therapeutics price target raised to $105 from $89 at Oppenheimer
07/28/20 Barclays
Crispr Therapeutics price target raised to $102 from $65 at Barclays
BEAM Beam Therapeutics
$19.00 /

+0.03 (+0.16%)

03/02/20
Fly Intel: Top five analyst initiations
03/02/20 Wedbush
Wedbush bullish on Beam Therapeutics, initiates with an Outperform
03/02/20 JPMorgan
Beam Therapeutics initiated with an Overweight at JPMorgan
03/02/20 Wedbush
Beam Therapeutics initiated with an Outperform at Wedbush
GBT Global Blood Therapeutics
$68.59 /

-2.08 (-2.94%)

07/20/20 Roth Capital
Global Blood Therapeutics initiated with a Buy at Roth Capital
07/13/20 BofA
Global Blood Therapeutics initiated with a Buy at BofA
07/01/20 Goldman Sachs
Global Blood Therapeutics upgraded to Buy from Neutral at Goldman Sachs
06/12/20 Wells Fargo
Global Blood's Oxbryta efficacy bar 'tough to surpass,' says Wells Fargo
IONS Ionis Pharmaceuticals
$58.45 /

-0.78 (-1.32%)

07/20/20 BMO Capital
Alnylam price target raised to $196 from $173 at BMO Capital
06/05/20 Citi
Ionis Pharmaceuticals price target raised to $80 from $71 at Citi
05/12/20 RBC Capital
Ionis Pharmaceuticals initiated with an Outperform at RBC Capital
04/22/20 Jefferies
Jefferies remains cautious on Ionis after report from partner Biogen
RTRX Retrophin
$20.19 /

+ (+0.00%)

07/13/20 BMO Capital
Retrophin price target lowered to $31 from $34 at BMO Capital
06/16/20 BTIG
Retrophin initiated with a Buy at BTIG
02/25/20 Barclays
Retrophin downgraded to Equal Weight from Overweight at Barclays
01/13/20 JMP Securities
JMP says continues to like Retrophin opportunity
XENE Xenon Pharmaceuticals
$11.51 /

+ (+0.00%)

TBIO Translate Bio
$15.60 /

-0.14 (-0.89%)

RTRX Retrophin
$20.19 /

+ (+0.00%)

RGEN Repligen
$155.50 /

-3.02 (-1.91%)

RCUS Arcus Biosciences
$20.42 /

-0.61 (-2.90%)

PIRS Pieris Pharmaceuticals
$2.68 /

-0.025 (-0.92%)

OVID Ovid Therapeutics
$6.61 /

-0.16 (-2.36%)

NCNA NuCana
$6.55 /

+0.4 (+6.50%)

NBIX Neurocrine
$124.09 /

+0.92 (+0.75%)

KRTX Karuna Therapeutics
$86.82 /

-0.68 (-0.78%)

ITCI Intra-Cellular
$20.77 /

-0.15 (-0.72%)

IONS Ionis Pharmaceuticals
$58.45 /

-0.78 (-1.32%)

GRTS Gritstone Oncology
$3.35 /

+0.03 (+0.90%)

GBT Global Blood Therapeutics
$68.59 /

-2.08 (-2.94%)

FATE Fate Therapeutics
$32.33 /

-0.92 (-2.77%)

EXEL Exelixis
$23.06 /

-0.64 (-2.70%)

EBS Emergent BioSolutions
$122.01 /

+4.045 (+3.43%)

CRSP Crispr Therapeutics
$91.70 /

-0.85 (-0.92%)

CLLS Cellectis
$17.44 /

+ (+0.00%)

CALA Calithera Biosciences
$4.85 /

-0.02 (-0.41%)

BEAM Beam Therapeutics
$19.00 /

+0.03 (+0.16%)

AXSM Axsome Therapeutics
$74.50 /

-1.82 (-2.38%)

AUTL Autolus Therapeutics
$13.92 /

+ (+0.00%)

ASMB Assembly Biosciences
$23.15 /

+0.03 (+0.13%)

ALLK Allakos
$78.92 /

-0.57 (-0.72%)

AGEN Agenus
$3.20 /

-0.055 (-1.69%)

ADPT Adaptive Biotechnologies
$39.49 /

+0.12 (+0.30%)

  • 16
    Jul
  • 01
    Jul
  • 26
    Jun
  • 09
    Jun
  • 09
    Jun
  • 29
    May
  • 13
    May
  • 16
    Apr
  • 06
    Feb
  • 23
    Jan
  • 23
    Jan
  • 22
    Jan
  • 24
    Jan
  • 08
    Jan
  • 19
    Dec
  • 12
    Dec
  • 21
    Nov
  • 21
    Nov
  • 04
    Oct
  • 18
    Sep
  • 12
    Sep
  • 12
    Sep
  • 07
    Aug
RCUS Arcus Biosciences
$20.42 /

-0.61 (-2.90%)

ALLK Allakos
$78.92 /

-0.57 (-0.72%)

TBIO Translate Bio
$15.60 /

-0.14 (-0.89%)

RCUS Arcus Biosciences
$20.42 /

-0.61 (-2.90%)

PIRS Pieris Pharmaceuticals
$2.68 /

-0.025 (-0.92%)

OVID Ovid Therapeutics
$6.61 /

-0.16 (-2.36%)

NCNA NuCana
$6.55 /

+0.4 (+6.50%)

NBIX Neurocrine
$124.09 /

+0.92 (+0.75%)

GBT Global Blood Therapeutics
$68.59 /

-2.08 (-2.94%)

FATE Fate Therapeutics
$32.33 /

-0.92 (-2.77%)

EXEL Exelixis
$23.06 /

-0.64 (-2.70%)

EBS Emergent BioSolutions
$122.01 /

+4.045 (+3.43%)

CRSP Crispr Therapeutics
$91.70 /

-0.85 (-0.92%)

CLLS Cellectis
$17.44 /

+ (+0.00%)

CALA Calithera Biosciences
$4.85 /

-0.02 (-0.41%)

BEAM Beam Therapeutics
$19.00 /

+0.03 (+0.16%)

AXSM Axsome Therapeutics
$74.50 /

-1.82 (-2.38%)

ALLK Allakos
$78.92 /

-0.57 (-0.72%)

ADPT Adaptive Biotechnologies
$39.49 /

+0.12 (+0.30%)

RCUS Arcus Biosciences
$20.42 /

-0.61 (-2.90%)

OVID Ovid Therapeutics
$6.61 /

-0.16 (-2.36%)

ITCI Intra-Cellular
$20.77 /

-0.15 (-0.72%)

IONS Ionis Pharmaceuticals
$58.45 /

-0.78 (-1.32%)

EXEL Exelixis
$23.06 /

-0.64 (-2.70%)

AXSM Axsome Therapeutics
$74.50 /

-1.82 (-2.38%)

Conference/Events
William Blair to hold a virtual conference » 08:49
08/04/20
08/04
08:49
08/04/20
08:49
RCUS

Arcus Biosciences

$21.03 /

+1.34 (+6.81%)

, AGEN

Agenus

$3.25 /

+0.205 (+6.73%)

, EXEL

Exelixis

$23.70 /

+0.64 (+2.78%)

, CALA

Calithera Biosciences

$4.87 /

+0.15 (+3.18%)

, RGEN

Repligen

$158.52 /

+7.46 (+4.94%)

, PIRS

Pieris Pharmaceuticals

$2.71 /

+0.135 (+5.25%)

, CYAD

Celyad

$9.87 /

+ (+0.00%)

, FATE

Fate Therapeutics

$33.25 /

+2 (+6.40%)

, CLLS

Cellectis

$17.44 /

+1.77 (+11.30%)

, AUTL

Autolus Therapeutics

$13.92 /

+0.72 (+5.45%)

, GRTS

Gritstone Oncology

$3.32 /

+0.115 (+3.59%)

, ADPT

Adaptive Biotechnologies

$39.37 /

+1.99 (+5.32%)

, TBIO

Translate Bio

$15.74 /

+0.56 (+3.69%)

, EBS

Emergent BioSolutions

$117.97 /

+6.755 (+6.07%)

, ITCI

Intra-Cellular

$20.92 /

+1.11 (+5.60%)

, KRTX

Karuna Therapeutics

$87.50 /

+5.89 (+7.22%)

, ASMB

Assembly Biosciences

$23.12 /

+0.9 (+4.05%)

, NCNA

NuCana

$6.15 /

+0.65 (+11.82%)

, AXSM

Axsome Therapeutics

$76.32 /

+4.97 (+6.97%)

, OVID

Ovid Therapeutics

$6.77 /

+0.32 (+4.96%)

, ALLK

Allakos

$79.49 /

+4.36 (+5.80%)

, NBIX

Neurocrine

$123.17 /

+2.8 (+2.33%)

, XENE

Xenon Pharmaceuticals

$11.51 /

+0.55 (+5.02%)

, CRSP

Crispr Therapeutics

$92.55 /

+7.15 (+8.37%)

, BEAM

Beam Therapeutics

$18.97 /

-0.31 (-1.61%)

, GBT

Global Blood Therapeutics

$70.67 /

+3.24 (+4.80%)

, IONS

Ionis Pharmaceuticals

$59.23 /

+1.7 (+2.95%)

, RTRX

Retrophin

$20.19 /

+0.385 (+1.94%)

Biotech Focus Virtual…

Biotech Focus Virtual Conference 2020 will be held on August 4-6 beginning at 10 am on August 4. Webcast Link

ShowHide Related Items >><<
XENE Xenon Pharmaceuticals
$11.51 /

+0.55 (+5.02%)

TBIO Translate Bio
$15.74 /

+0.56 (+3.69%)

RTRX Retrophin
$20.19 /

+0.385 (+1.94%)

RGEN Repligen
$158.52 /

+7.46 (+4.94%)

RCUS Arcus Biosciences
$21.03 /

+1.34 (+6.81%)

PIRS Pieris Pharmaceuticals
$2.71 /

+0.135 (+5.25%)

OVID Ovid Therapeutics
$6.77 /

+0.32 (+4.96%)

NCNA NuCana
$6.15 /

+0.65 (+11.82%)

NBIX Neurocrine
$123.17 /

+2.8 (+2.33%)

KRTX Karuna Therapeutics
$87.50 /

+5.89 (+7.22%)

ITCI Intra-Cellular
$20.92 /

+1.11 (+5.60%)

IONS Ionis Pharmaceuticals
$59.23 /

+1.7 (+2.95%)

GRTS Gritstone Oncology
$3.32 /

+0.115 (+3.59%)

GBT Global Blood Therapeutics
$70.67 /

+3.24 (+4.80%)

FATE Fate Therapeutics
$33.25 /

+2 (+6.40%)

EXEL Exelixis
$23.70 /

+0.64 (+2.78%)

EBS Emergent BioSolutions
$117.97 /

+6.755 (+6.07%)

CYAD Celyad
$9.87 /

+ (+0.00%)

CRSP Crispr Therapeutics
$92.55 /

+7.15 (+8.37%)

CLLS Cellectis
$17.44 /

+1.77 (+11.30%)

CALA Calithera Biosciences
$4.87 /

+0.15 (+3.18%)

BEAM Beam Therapeutics
$18.97 /

-0.31 (-1.61%)

AXSM Axsome Therapeutics
$76.32 /

+4.97 (+6.97%)

AUTL Autolus Therapeutics
$13.92 /

+0.72 (+5.45%)

ASMB Assembly Biosciences
$23.12 /

+0.9 (+4.05%)

ALLK Allakos
$79.49 /

+4.36 (+5.80%)

AGEN Agenus
$3.25 /

+0.205 (+6.73%)

ADPT Adaptive Biotechnologies
$39.37 /

+1.99 (+5.32%)

RCUS Arcus Biosciences
$21.03 /

+1.34 (+6.81%)

06/10/20 Truist
Arcus Biosciences price target raised to $45 from $22 at SunTrust
06/03/20 SVB Leerink
Gilead upgraded to Outperform at SVB Leerink on remdesivir sales, Arcus deal
06/02/20 Citi
Arcus Biosciences price target raised to $41 from $15 at Citi
05/27/20 Raymond James
Raymond James keeps Market Perform on Gilead following Arcus partnership
AGEN Agenus
$3.25 /

+0.205 (+6.73%)

01/09/20 B. Riley FBR
Arbutus Biopharma price target raised to $6 from $3 at B. Riley FBR
11/19/19
Fly Intel: Top five analyst initiations
11/19/19 B. Riley FBR
Agenus resumed with a Buy at B. Riley FBR
11/19/19 B. Riley FBR
Agenus resumed with a Buy at B. Riley FBR
EXEL Exelixis
$23.70 /

+0.64 (+2.78%)

06/30/20 Piper Sandler
Exelixis' 2/3 Phase III Contact studies underway, says Piper Sandler
05/14/20 Truist
Exelixis price target raised to $40 from $35 at SunTrust
05/13/20 Piper Sandler
Exelixis mCRPC data for CABOMETYX may accelerate approval, says Piper Sandler
05/06/20 Piper Sandler
Exelixis price target raised to $30 from $23 at Piper Sandler
CALA Calithera Biosciences
$4.87 /

+0.15 (+3.18%)

05/11/20 Citi
Calithera Biosciences price target raised to $10 from $7 at Citi
05/08/20 H.C. Wainwright
Calithera Biosciences price target raised to $9.50 from $7 at H.C. Wainwright
03/27/20
Fly Intel: Top five analyst initiations
03/27/20 Jefferies
Jefferies starts Calithera at Buy ahead of three data catalysts
RGEN Repligen
$158.52 /

+7.46 (+4.94%)

06/30/20 H.C. Wainwright
Repligen price target raised to $151 from $143 at H.C. Wainwright
05/27/20 Stifel
Repligen price target raised to $150 from $135 at Stifel
05/07/20 Craig-Hallum
Repligen price target raised to $145 from $120 at Craig-Hallum
05/07/20 H.C. Wainwright
Repligen price target raised to $143 from $100 at H.C. Wainwright
PIRS Pieris Pharmaceuticals
$2.71 /

+0.135 (+5.25%)

03/13/20 Baird
Baird upgrades Pieris Pharmaceuticals as pipeline updates expected
03/13/20 Baird
Pieris Pharmaceuticals upgraded to Outperform from Neutral at Baird
03/12/20 H.C. Wainwright
Increased visibility in 2020 expected for Pieris, says H.C. Wainwright
01/27/20 H.C. Wainwright
Pieris Pharmaceuticals price target raised to $9 from $7 at H.C. Wainwright
CYAD Celyad
$9.87 /

+ (+0.00%)

03/26/20 Wells Fargo
Celyad price target lowered to $20 from $44 at Wells Fargo
03/25/20 H.C. Wainwright
Celyad price target lowered to $37 from $43 at H.C. Wainwright
FATE Fate Therapeutics
$33.25 /

+2 (+6.40%)

06/10/20 Oppenheimer
Fate Therapeutics price target raised to $40 from $34 at Oppenheimer
06/09/20 Piper Sandler
Fate Therapeutics price target lowered to $59 from $63 at Piper Sandler
05/13/20
Fly Intel: Top five analyst initiations
05/13/20 H.C. Wainwright
Fate Therapeutics initiated with a Buy at H.C. Wainwright
CLLS Cellectis
$17.44 /

+1.77 (+11.30%)

05/12/20
Fly Intel: Top five analyst initiations
05/11/20 Baird
Cellectis initiated with an Outperform at Baird
03/06/20 Citi
Cellectis price target raised to $16 from $14 at Citi
03/06/20 Goldman Sachs
Cellectis downgraded to Sell from Neutral at Goldman Sachs
AUTL Autolus Therapeutics
$13.92 /

+0.72 (+5.45%)

07/31/20
Fly Intel: Top five analyst initiations
07/31/20 JPMorgan
Autolus Therapeutics initiated with an Overweight at JPMorgan
07/22/20 Truist
Autolus Therapeutics initiated with a Buy at SunTrust
07/22/20 Truist
Autolus Therapeutics initiated with a Buy at SunTrust
GRTS Gritstone Oncology
$3.32 /

+0.115 (+3.59%)

07/14/20 BTIG
Gritstone Oncology price target lowered to $17 from $31 at BTIG
ADPT Adaptive Biotechnologies
$39.37 /

+1.99 (+5.32%)

06/18/20 Guggenheim
Adaptive to benefit from increased MRD testing by oncologists, says Guggenheim
06/03/20
Fly Intel: Top five analyst initiations
06/03/20 Goldman Sachs
Adaptive Biotechnologies initiated with a Buy at Goldman Sachs
05/19/20 Guggenheim
Adaptive Biotechnologies price target raised to $50 from $44 at Guggenheim
TBIO Translate Bio
$15.74 /

+0.56 (+3.69%)

07/07/20 H.C. Wainwright
Translate Bio price target raised to $32 from $18 at H.C. Wainwright
07/06/20
Fly Intel: Top five analyst initiations
07/06/20 William Blair
Translate Bio initiated with an Outperform at William Blair
06/26/20 Truist
Translate Bio initiated with a Buy at SunTrust
EBS Emergent BioSolutions
$117.97 /

+6.755 (+6.07%)

07/17/20 Cantor Fitzgerald
Emergent BioSolutions price target raised to $110 from $85 at Cantor Fitzgerald
07/02/20 Wells Fargo
Emergent BioSolutions price target raised to $93 from $85 at Wells Fargo
06/26/20 Raymond James
Vaxart already had vaccine deals with Emergent, Kindred, notes Raymond James
06/08/20 Guggenheim
Emergent BioSolutions price target lowered to $87 from $101 at Guggenheim
ITCI Intra-Cellular
$20.92 /

+1.11 (+5.60%)

06/04/20 Cantor Fitzgerald
Cantor reiterates $37 target on Intra-Cellular ahead of Phase 3 data
03/03/20 BTIG
Intra-Cellular price target lowered to $68 from $73 at BTIG
02/20/20
Fly Intel: Top five analyst initiations
02/19/20 Evercore ISI
Intra-Cellular initiated with an Outperform at Evercore ISI
KRTX Karuna Therapeutics
$87.50 /

+5.89 (+7.22%)

06/24/20 Oppenheimer
Karuna Therapeutics price target raised to $135 from $125 at Oppenheimer
06/02/20 Wedbush
Karuna Therapeutics price target raised to $126 from $117 at Wedbush
06/01/20 Goldman Sachs
Karuna price target raised to $131 from $115 at Goldman Sachs
05/31/20 Stifel
Karuna schizophrenia drug has blockbuster potential, says Stifel
ASMB Assembly Biosciences
$23.12 /

+0.9 (+4.05%)

07/21/20 Baird
Assembly Biosciences HBV deal a positive, says Baird
07/20/20 Piper Sandler
BeiGene inked smart deal with Assembly, says Piper Sandler
06/02/20 Mizuho
New clinical paper potentially supports Assembly stoppage criteria, says Mizuho
10/17/19 Baird
Assembly Biosciences abstract data encouraging, says Baird
NCNA NuCana
$6.15 /

+0.65 (+11.82%)

07/24/20
Fly Intel: Top five analyst initiations
07/24/20 Oppenheimer
NuCana initiated with an Outperform at Oppenheimer
07/23/20 Oppenheimer
NuCana initiated with an Outperform at Oppenheimer
01/27/20 William Blair
NuCana undervalued as first patients dosed in Phase 3 study, says William Blair
AXSM Axsome Therapeutics
$76.32 /

+4.97 (+6.97%)

07/13/20 Oppenheimer
Relmada Therapeutics initiated with an Outperform at Oppenheimer
04/28/20 Guggenheim
Axsome Therapeutics price target raised to $200 from $158 at Guggenheim
04/28/20 Truist
Axsome Therapeutics price target raised to $200 from $145 at SunTrust
04/28/20 Cantor Fitzgerald
Axsome Therapeutics price target raised to $131 from $125 at Cantor Fitzgerald
OVID Ovid Therapeutics
$6.77 /

+0.32 (+4.96%)

07/14/20 Citi
Ovid Therapeutics price target raised to $9 from $8 at Citi
06/18/20 Cantor Fitzgerald
Ovid Therapeutics price target raised to $13 from $7 at Cantor Fitzgerald
05/22/20 Cantor Fitzgerald
Zynerba price target raised to $21 from $12 at Cantor Fitzgerald
05/07/20 Piper Sandler
Ovid's gaboxadol data in Fragile X 'promising,' says Piper Sandler
ALLK Allakos
$79.49 /

+4.36 (+5.80%)

03/25/20 Jefferies
Allakos starts two pivotals on time despite skepticism, says Jefferies
03/12/20 SMBC Nikko
Allakos initiated with an Underperform at SMBC Nikko
02/27/20 Barclays
Allakos initiated with an Underweight at Barclays
02/27/20 Barclays
Allakos initiated with an Underweight at Barclays
NBIX Neurocrine
$123.17 /

+2.8 (+2.33%)

08/04/20 Canaccord
Neurocrine price target raised to $145 from $134 at Canaccord
08/04/20 SVB Leerink
Neurocrine price target raised to $120 from $105 at SVB Leerink
08/04/20 Piper Sandler
Neurocrine price target raised to $145 from $141 at Piper Sandler
08/04/20 H.C. Wainwright
Neurocrine price target raised to $140 from $131 at H.C. Wainwright
XENE Xenon Pharmaceuticals
$11.51 /

+0.55 (+5.02%)

07/21/20
Fly Intel: Top five analyst initiations
07/21/20 Needham
Xenon Pharmaceuticals initiated with a Buy at Needham
07/20/20 Needham
Xenon Pharmaceuticals initiated with a Buy at Needham
06/01/20
Fly Intel: Top five analyst initiations
CRSP Crispr Therapeutics
$92.55 /

+7.15 (+8.37%)

07/28/20 Needham
Crispr Therapeutics price target raised to $105 from $84 at Needham
07/28/20 Wells Fargo
Crispr Therapeutics price target raised to $110 from $95 at Wells Fargo
07/28/20 Oppenheimer
Crispr Therapeutics price target raised to $105 from $89 at Oppenheimer
07/28/20 Barclays
Crispr Therapeutics price target raised to $102 from $65 at Barclays
BEAM Beam Therapeutics
$18.97 /

-0.31 (-1.61%)

03/02/20
Fly Intel: Top five analyst initiations
03/02/20 Wedbush
Wedbush bullish on Beam Therapeutics, initiates with an Outperform
03/02/20 JPMorgan
Beam Therapeutics initiated with an Overweight at JPMorgan
03/02/20 Wedbush
Beam Therapeutics initiated with an Outperform at Wedbush
GBT Global Blood Therapeutics
$70.67 /

+3.24 (+4.80%)

07/20/20 Roth Capital
Global Blood Therapeutics initiated with a Buy at Roth Capital
07/13/20 BofA
Global Blood Therapeutics initiated with a Buy at BofA
07/01/20 Goldman Sachs
Global Blood Therapeutics upgraded to Buy from Neutral at Goldman Sachs
06/12/20 Wells Fargo
Global Blood's Oxbryta efficacy bar 'tough to surpass,' says Wells Fargo
IONS Ionis Pharmaceuticals
$59.23 /

+1.7 (+2.95%)

07/20/20 BMO Capital
Alnylam price target raised to $196 from $173 at BMO Capital
06/05/20 Citi
Ionis Pharmaceuticals price target raised to $80 from $71 at Citi
05/12/20 RBC Capital
Ionis Pharmaceuticals initiated with an Outperform at RBC Capital
04/22/20 Jefferies
Jefferies remains cautious on Ionis after report from partner Biogen
RTRX Retrophin
$20.19 /

+0.385 (+1.94%)

07/13/20 BMO Capital
Retrophin price target lowered to $31 from $34 at BMO Capital
06/16/20 BTIG
Retrophin initiated with a Buy at BTIG
02/25/20 Barclays
Retrophin downgraded to Equal Weight from Overweight at Barclays
01/13/20 JMP Securities
JMP says continues to like Retrophin opportunity
XENE Xenon Pharmaceuticals
$11.51 /

+0.55 (+5.02%)

TBIO Translate Bio
$15.74 /

+0.56 (+3.69%)

RTRX Retrophin
$20.19 /

+0.385 (+1.94%)

RGEN Repligen
$158.52 /

+7.46 (+4.94%)

RCUS Arcus Biosciences
$21.03 /

+1.34 (+6.81%)

PIRS Pieris Pharmaceuticals
$2.71 /

+0.135 (+5.25%)

OVID Ovid Therapeutics
$6.77 /

+0.32 (+4.96%)

NCNA NuCana
$6.15 /

+0.65 (+11.82%)

NBIX Neurocrine
$123.17 /

+2.8 (+2.33%)

KRTX Karuna Therapeutics
$87.50 /

+5.89 (+7.22%)

ITCI Intra-Cellular
$20.92 /

+1.11 (+5.60%)

IONS Ionis Pharmaceuticals
$59.23 /

+1.7 (+2.95%)

GRTS Gritstone Oncology
$3.32 /

+0.115 (+3.59%)

GBT Global Blood Therapeutics
$70.67 /

+3.24 (+4.80%)

FATE Fate Therapeutics
$33.25 /

+2 (+6.40%)

EXEL Exelixis
$23.70 /

+0.64 (+2.78%)

EBS Emergent BioSolutions
$117.97 /

+6.755 (+6.07%)

CRSP Crispr Therapeutics
$92.55 /

+7.15 (+8.37%)

CLLS Cellectis
$17.44 /

+1.77 (+11.30%)

CALA Calithera Biosciences
$4.87 /

+0.15 (+3.18%)

BEAM Beam Therapeutics
$18.97 /

-0.31 (-1.61%)

AXSM Axsome Therapeutics
$76.32 /

+4.97 (+6.97%)

AUTL Autolus Therapeutics
$13.92 /

+0.72 (+5.45%)

ASMB Assembly Biosciences
$23.12 /

+0.9 (+4.05%)

ALLK Allakos
$79.49 /

+4.36 (+5.80%)

AGEN Agenus
$3.25 /

+0.205 (+6.73%)

ADPT Adaptive Biotechnologies
$39.37 /

+1.99 (+5.32%)

  • 16
    Jul
  • 01
    Jul
  • 26
    Jun
  • 09
    Jun
  • 09
    Jun
  • 29
    May
  • 13
    May
  • 16
    Apr
  • 06
    Feb
  • 23
    Jan
  • 23
    Jan
  • 22
    Jan
  • 24
    Jan
  • 08
    Jan
  • 19
    Dec
  • 12
    Dec
  • 21
    Nov
  • 21
    Nov
  • 04
    Oct
  • 18
    Sep
  • 12
    Sep
  • 12
    Sep
  • 07
    Aug
RCUS Arcus Biosciences
$21.03 /

+1.34 (+6.81%)

ALLK Allakos
$79.49 /

+4.36 (+5.80%)

TBIO Translate Bio
$15.74 /

+0.56 (+3.69%)

RCUS Arcus Biosciences
$21.03 /

+1.34 (+6.81%)

PIRS Pieris Pharmaceuticals
$2.71 /

+0.135 (+5.25%)

OVID Ovid Therapeutics
$6.77 /

+0.32 (+4.96%)

NCNA NuCana
$6.15 /

+0.65 (+11.82%)

NBIX Neurocrine
$123.17 /

+2.8 (+2.33%)

GBT Global Blood Therapeutics
$70.67 /

+3.24 (+4.80%)

FATE Fate Therapeutics
$33.25 /

+2 (+6.40%)

EXEL Exelixis
$23.70 /

+0.64 (+2.78%)

EBS Emergent BioSolutions
$117.97 /

+6.755 (+6.07%)

CRSP Crispr Therapeutics
$92.55 /

+7.15 (+8.37%)

CLLS Cellectis
$17.44 /

+1.77 (+11.30%)

CALA Calithera Biosciences
$4.87 /

+0.15 (+3.18%)

BEAM Beam Therapeutics
$18.97 /

-0.31 (-1.61%)

AXSM Axsome Therapeutics
$76.32 /

+4.97 (+6.97%)

ALLK Allakos
$79.49 /

+4.36 (+5.80%)

ADPT Adaptive Biotechnologies
$39.37 /

+1.99 (+5.32%)

RCUS Arcus Biosciences
$21.03 /

+1.34 (+6.81%)

OVID Ovid Therapeutics
$6.77 /

+0.32 (+4.96%)

ITCI Intra-Cellular
$20.92 /

+1.11 (+5.60%)

IONS Ionis Pharmaceuticals
$59.23 /

+1.7 (+2.95%)

EXEL Exelixis
$23.70 /

+0.64 (+2.78%)

AXSM Axsome Therapeutics
$76.32 /

+4.97 (+6.97%)

Conference/Events
Micron participates in a conference call with Mizuho » 04:55
08/04/20
08/04
04:55
08/04/20
04:55
MU

Micron

$50.36 /

+0.31 (+0.62%)

Conference call with…

Conference call with management will be held on August 4 hosted by Mizuho.

ShowHide Related Items >><<
MU Micron
$50.36 /

+0.31 (+0.62%)

MU Micron
$50.36 /

+0.31 (+0.62%)

07/28/20 Cleveland Research
Cleveland Research sees sharper pricing downside for DRAM and NAND
07/23/20 Raymond James
SK hynx's report generally consistent with Micron's, says Raymond James
06/30/20 RBC Capital
Micron price target raised to $60 from $55 at RBC Capital
06/30/20 Morgan Stanley
Morgan Stanley would add to Micron positions on weakness in coming 'rough patch'
MU Micron
$50.36 /

+0.31 (+0.62%)

MU Micron
$50.36 /

+0.31 (+0.62%)

MU Micron
$50.36 /

+0.31 (+0.62%)

MU Micron
$50.36 /

+0.31 (+0.62%)

Friday
Conference/Events
Micron participates in a conference call with Mizuho » 17:27
07/31/20
07/31
17:27
07/31/20
17:27
MU

Micron

$50.05 /

-0.69 (-1.36%)

Conference call with…

Conference call with management will be held on August 4 hosted by Mizuho.

ShowHide Related Items >><<
MU Micron
$50.05 /

-0.69 (-1.36%)

MU Micron
$50.05 /

-0.69 (-1.36%)

07/28/20 Cleveland Research
Cleveland Research sees sharper pricing downside for DRAM and NAND
07/23/20 Raymond James
SK hynx's report generally consistent with Micron's, says Raymond James
06/30/20 RBC Capital
Micron price target raised to $60 from $55 at RBC Capital
06/30/20 Morgan Stanley
Morgan Stanley would add to Micron positions on weakness in coming 'rough patch'
MU Micron
$50.05 /

-0.69 (-1.36%)

MU Micron
$50.05 /

-0.69 (-1.36%)

MU Micron
$50.05 /

-0.69 (-1.36%)

MU Micron
$50.05 /

-0.69 (-1.36%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.